510(k) · Cleared
ClearedLiaison XL Analyzer Model 10050
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
DiaSorin, Inc. · LOL Hepatitis A Test (Antibody And Igm Antibody)
Cleared on Jan 21, 2011 as substantially equivalent to K082050 (DiaSorin, Inc., 2008) and 1 other predicate after a 51-day review. Its family tree reaches back 2 generations to 1990. 2 later devices descend from it.
- Decided
- Jan 21, 2011
- Review
- 51 days
- Class
- Class II
- Product code
- LOL
- Recalls
- None
- Predicates
- 2
Its longest line of descent runs back 2 generations to P890014 (1990). 3 ancestors in all. 2 later devices descend from it, 1 citing it directly.
- Root · 2 generations backP890014 HA-Igmk and Eti-HA-IgmkDiaSorin, Inc. · 1990 · Recalled
- 1 generation backK082050 Liaison Hav Igm Assay, Liaison Control Hav IgmDiaSorin, Inc. · 2008
- This deviceK103529 Liaison XL Analyzer Model 10050DiaSorin, Inc. · 2011
- Descendant · cites it directly · 1 of its ownK141116 Liaison XL AnalyzerDiaSorin, Inc. · 2014
- Descendant · 2 generations on · 0 of its ownK260770 LIAISON Murex HBsAg Qual; LIAISON XL; LIAISON diluteXDiaSorin, Inc. · 2026
Most influential descendants
Showing 2 of 2 · See allView FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −2 | P890014 | HA-Igmk and Eti-HA-Igmk | DiaSorin, Inc. | 1990 | 1 |
| −1 | K082050 | Liaison Hav Igm Assay, Liaison Control Hav Igm | DiaSorin, Inc. | 2008 | — |
| 0 (this device) | K103529 | Liaison XL Analyzer Model 10050 | DiaSorin, Inc. | 2011 | — |
| +1 | K141116 | Liaison XL Analyzer | DiaSorin, Inc. | 2014 | — |
| +2 | K260770 | LIAISON Murex HBsAg Qual; LIAISON XL; LIAISON diluteX | DiaSorin, Inc. | 2026 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2004 | 1 | 0 |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2014 | 1 | 0 |
| 2026 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in LOL? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new LOL device
- #1 K251995 Access anti-HAV IgMscore 13.8 · 1 generation · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (2)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K082050 | Liaison Hav Igm Assay, Liaison Control Hav IgmSummary page 1…LOL, JJF PREDICATE DEVICES: LIAISON® Analyzer Reference K082050 DEVICE DESCRIPTION: INTENDED USE: The LIAISON® Anti-HAV assay is an in vitro chemiluminescent immunoassay intended for the qual… | 2008 |
| * | K032844 | Liaison 25 OH Vitamin DSummary page 3…s and Differences: Feature LIAISON8' Analyzer LIAISON8' XL Analyzer FDA K# K032844/K082050 N/A Intended Use Automated chemiluminescent Same… | 2004 |
What descends from it? (2)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K141116 | Liaison XL Analyzer | 2014 | 1 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 21 years and passes through 1 company; a new generation was cleared every 18.3 years on median.
- 2 of the 3 ancestors have a recall of any class.
- Of its descendants, K141116 (DiaSorin, Inc., 2014) has gone furthest, with 1 descendant of its own.
How does its category compare?
All LOL devicesLOL Hepatitis A Test (Antibody And Igm Antibody): FDA decisions, review times, recalls and adverse event reports over 20 years. 2011, this device’s year, is highlighted.
FDA decisions per year · LOL
1in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · LOL
108in 2008
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · LOL
2in 2019
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · LOL
19in 2025
MAUDE reports naming product code LOL, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 3 | 182 | 2 | 2 |
| 2008 | 3 | 108 | 1 | 13 |
| 2009 | 2 | — | 1 | 24 |
| 2010 | 2 | — | 0 | 53 |
| 2011 | 1 | — | 1 | 353 |
| 2012 | 1 | — | 0 | 42 |
| 2013 | 0 | — | 0 | 49 |
| 2014 | 2 | — | 0 | 19 |
| 2015 | 0 | — | 0 | 29 |
| 2016 | 2 | — | 0 | 36 |
| 2017 | 0 | — | 0 | 26 |
| 2018 | 0 | — | 1 | 61 |
| 2019 | 1 | — | 2 | 51 |
| 2020 | 1 | — | 0 | 104 |
| 2021 | 1 | — | 0 | 12 |
| 2022 | 1 | — | 0 | 17 |
| 2023 | 1 | — | 0 | 36 |
| 2024 | 0 | — | 0 | 21 |
| 2025 | 1 | — | 0 | 19 |
| 2026 | 2 | — | 0 | — |
What is it indicated for?
The LIAISON® Anti-HAy assay is an in vitro chemiluminescent immunoassay intended for the qualitative detection of total antibodies to hepatitis A (anti-HAy) in human serum and sodium heparin plasma samples using the LIAISON® Analyzer family. The assay is indicated as an aid in the laboratory diagnosis of current or previous HAV infections in conjunction with other serological and clinical information and to determine the presence of an antibody response…
Read the full statement (236 words)
The LIAISON® Anti-HAy assay is an in vitro chemiluminescent immunoassay intended for the qualitative detection of total antibodies to hepatitis A (anti-HAy) in human serum and sodium heparin plasma samples using the LIAISON® Analyzer family. The assay is indicated as an aid in the laboratory diagnosis of current or previous HAV infections in conjunction with other serological and clinical information and to determine the presence of an antibody response to HAV in vaccine recipients.
This assay is not intended for screening blood or solid or soft tissue donors. Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients. The user is responsible for establishing assay performance characteristics in these populations. Caution: U.S. Federal Law restricts this device to sale by or on the order of a physician.
The LIAISON® XL Analyzer is an automated discrete continuous loading chemiluminescent immunoassay (CLIA) analyzer for in vitro diagnostic analysis of CLIAs on human serum or plasma. The system menu includes infectious disease, bone and mineral, and endocrinology CLIAs. It is to be used only with FDA cleared chemiluminescence immunoassays that are marketed by DiaSorin for the LIAISON XL Analyzer.
The LIAISON® Control Anti-HAV (negative and positive) is intended for use as assayed quality control samples to monitor the performance of the LIAISON® Anti-HAy assay.
The performance characteristics of LIAISON® controls have not been established for any other assays or instrument platforms different from LIAISON® and LIAISON® XL.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K103529 · printed Nov 4, 2026
Cite this page
510(k) Report. “K103529: Liaison XL Analyzer Model 10050.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K103529
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026